Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Fluticasone Furoate (FF)/GW642444 Inhalation Powder and the Individual Components in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

ClinicalTrials.gov ID: NCT01054885

Public ClinicalTrials.gov record NCT01054885. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 23, 2026, 2:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A 24-Week Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder and the Individual Components Delivered Once Daily (AM) Via a Novel Dry Powder Inhaler Compared With Placebo in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Study identification

NCT ID
NCT01054885
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
GlaxoSmithKline
Industry
Enrollment
1,226 participants

Conditions and interventions

Interventions

  • FF Inhalation Powder Drug
  • FF/GW642444 Inhalation Powder Drug
  • GW642444 Inhalation Powder Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
40 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 18, 2009
Primary completion
Jan 31, 2011
Completion
Feb 7, 2011
Last update posted
Jan 23, 2018

2009 – 2011

United States locations

U.S. sites
49
U.S. states
19
U.S. cities
49
Facility City State ZIP Site status
GSK Investigational Site Birmingham Alabama 35235
GSK Investigational Site Jasper Alabama 35501
GSK Investigational Site Lakewood California 90712
GSK Investigational Site Long Beach California 90808
GSK Investigational Site Los Angeles California 90048
GSK Investigational Site Monterey Park California 91754
GSK Investigational Site National City California 91950
GSK Investigational Site Oxnard California 93030-5841
GSK Investigational Site San Diego California 92120
GSK Investigational Site Santa Monica California 90404
GSK Investigational Site Wilmington Delaware 19805
GSK Investigational Site Bay Pines Florida 33744
GSK Investigational Site Brandon Florida 33511
GSK Investigational Site Clearwater Florida 33756
GSK Investigational Site Cocoa Florida 32927
GSK Investigational Site Fort Lauderdale Florida 33316
GSK Investigational Site Pensacola Florida 32503
GSK Investigational Site Decatur Georgia
GSK Investigational Site Gainesville Georgia
GSK Investigational Site Martinez Georgia 30907
GSK Investigational Site Lenexa Kansas 66215
GSK Investigational Site Wheaton Maryland 20902
GSK Investigational Site Saint Charles Missouri 63301
GSK Investigational Site Cherry Hill New Jersey 08003
GSK Investigational Site Ocean City New Jersey 7712
GSK Investigational Site Brooklyn New York 11229
GSK Investigational Site Elizabeth City North Carolina 27909
GSK Investigational Site Statesville North Carolina 28625
GSK Investigational Site Cincinnati Ohio 45231
GSK Investigational Site Dayton Ohio 45439
GSK Investigational Site Oklahoma City Oklahoma 73103
GSK Investigational Site Tulsa Oklahoma 74136-8303
GSK Investigational Site Medford Oregon 97504
GSK Investigational Site Portland Oregon 97213
GSK Investigational Site Columbia South Carolina 29203
GSK Investigational Site Easley South Carolina 29640
GSK Investigational Site Gaffney South Carolina 29340
GSK Investigational Site Orangeburg South Carolina 29118
GSK Investigational Site Seneca South Carolina 29678
GSK Investigational Site Spartanburg South Carolina 29303
GSK Investigational Site Union South Carolina 29379
GSK Investigational Site Johnson City Tennessee 37601
GSK Investigational Site New Tazewell Tennessee 37825
GSK Investigational Site Boerne Texas 78006
GSK Investigational Site Corsicana Texas 75110
GSK Investigational Site Kingwood Texas 77339
GSK Investigational Site Temple Texas 76508
GSK Investigational Site Fredericksburg Virginia 22401
GSK Investigational Site Morgantown West Virginia 26505

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 100 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01054885, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 23, 2018 · Synced Jul 23, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01054885 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →